Cargando…

The investigation of Strongyloides stercoralis seroprevalence in immunosupressed patients in Turkey

BACKGROUND/AIM: In immunosuppressed patients, strongyloidiasis can be lifethreatening because of hyperinfection or dissemination. Therefore, diagnosis of S. stercoralis is important in immunosuppressed patients with chronic strongyloidiasis. In this study, our objective was to investigate the presen...

Descripción completa

Detalles Bibliográficos
Autores principales: KAYA, Filiz, İNKAYA, Ahmet Çağkan, ERTENLİ, Ali İhsan, ABBASOĞLU, Osman, AKSOY, Sercan, AKYÖN YILMAZ, Yakut, ERGÜVEN, Sibel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Scientific and Technological Research Council of Turkey 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350872/
https://www.ncbi.nlm.nih.gov/pubmed/30761833
http://dx.doi.org/10.3906/sag-1804-16
_version_ 1783557352632352768
author KAYA, Filiz
İNKAYA, Ahmet Çağkan
ERTENLİ, Ali İhsan
ABBASOĞLU, Osman
AKSOY, Sercan
AKYÖN YILMAZ, Yakut
ERGÜVEN, Sibel
author_facet KAYA, Filiz
İNKAYA, Ahmet Çağkan
ERTENLİ, Ali İhsan
ABBASOĞLU, Osman
AKSOY, Sercan
AKYÖN YILMAZ, Yakut
ERGÜVEN, Sibel
author_sort KAYA, Filiz
collection PubMed
description BACKGROUND/AIM: In immunosuppressed patients, strongyloidiasis can be lifethreatening because of hyperinfection or dissemination. Therefore, diagnosis of S. stercoralis is important in immunosuppressed patients with chronic strongyloidiasis. In this study, our objective was to investigate the presence of S. stercoralis antibodies by an ELISA method in immunosuppressed patients. MATERIALS AND METHODS: A total of 100 immunosuppressed patients’ sera were included in the study. Forty-two of the patients were receiving immunosuppressive therapies for cancer or being treated for hematopoietic malignancies, 38 of the patients were receiving immunosuppressive drugs for rheumatic diseases, 14 were receiving immunosuppressive therapies for liver transplantation. Two of the patients were being treated for HIV infection and 4 were being treated for hypogammaglobulinemia. As control group, 50 individuals without a known disease were included in the study. The presence of IgG antibodies against S. stercoralis was investigated with a commercial ELISA kit. RESULTS: S. stercoralis antibody test was positive in 4 of 100 (4%) sera from immunosuppressed patients. All control patients were negative for S. stercoralis. CONCLUSION: Strongyloidiasis can be a lifelong chronic infection if not treated. In patients who are going to receive immunosuppressive therapy, it should be tested before treatment, as it can become a disseminated and life-threatening infectious disease.
format Online
Article
Text
id pubmed-7350872
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher The Scientific and Technological Research Council of Turkey
record_format MEDLINE/PubMed
spelling pubmed-73508722020-07-13 The investigation of Strongyloides stercoralis seroprevalence in immunosupressed patients in Turkey KAYA, Filiz İNKAYA, Ahmet Çağkan ERTENLİ, Ali İhsan ABBASOĞLU, Osman AKSOY, Sercan AKYÖN YILMAZ, Yakut ERGÜVEN, Sibel Turk J Med Sci Article BACKGROUND/AIM: In immunosuppressed patients, strongyloidiasis can be lifethreatening because of hyperinfection or dissemination. Therefore, diagnosis of S. stercoralis is important in immunosuppressed patients with chronic strongyloidiasis. In this study, our objective was to investigate the presence of S. stercoralis antibodies by an ELISA method in immunosuppressed patients. MATERIALS AND METHODS: A total of 100 immunosuppressed patients’ sera were included in the study. Forty-two of the patients were receiving immunosuppressive therapies for cancer or being treated for hematopoietic malignancies, 38 of the patients were receiving immunosuppressive drugs for rheumatic diseases, 14 were receiving immunosuppressive therapies for liver transplantation. Two of the patients were being treated for HIV infection and 4 were being treated for hypogammaglobulinemia. As control group, 50 individuals without a known disease were included in the study. The presence of IgG antibodies against S. stercoralis was investigated with a commercial ELISA kit. RESULTS: S. stercoralis antibody test was positive in 4 of 100 (4%) sera from immunosuppressed patients. All control patients were negative for S. stercoralis. CONCLUSION: Strongyloidiasis can be a lifelong chronic infection if not treated. In patients who are going to receive immunosuppressive therapy, it should be tested before treatment, as it can become a disseminated and life-threatening infectious disease. The Scientific and Technological Research Council of Turkey 2019-02-11 /pmc/articles/PMC7350872/ /pubmed/30761833 http://dx.doi.org/10.3906/sag-1804-16 Text en Copyright © 2019 The Author(s) This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Article
KAYA, Filiz
İNKAYA, Ahmet Çağkan
ERTENLİ, Ali İhsan
ABBASOĞLU, Osman
AKSOY, Sercan
AKYÖN YILMAZ, Yakut
ERGÜVEN, Sibel
The investigation of Strongyloides stercoralis seroprevalence in immunosupressed patients in Turkey
title The investigation of Strongyloides stercoralis seroprevalence in immunosupressed patients in Turkey
title_full The investigation of Strongyloides stercoralis seroprevalence in immunosupressed patients in Turkey
title_fullStr The investigation of Strongyloides stercoralis seroprevalence in immunosupressed patients in Turkey
title_full_unstemmed The investigation of Strongyloides stercoralis seroprevalence in immunosupressed patients in Turkey
title_short The investigation of Strongyloides stercoralis seroprevalence in immunosupressed patients in Turkey
title_sort investigation of strongyloides stercoralis seroprevalence in immunosupressed patients in turkey
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350872/
https://www.ncbi.nlm.nih.gov/pubmed/30761833
http://dx.doi.org/10.3906/sag-1804-16
work_keys_str_mv AT kayafiliz theinvestigationofstrongyloidesstercoralisseroprevalenceinimmunosupressedpatientsinturkey
AT inkayaahmetcagkan theinvestigationofstrongyloidesstercoralisseroprevalenceinimmunosupressedpatientsinturkey
AT ertenlialiihsan theinvestigationofstrongyloidesstercoralisseroprevalenceinimmunosupressedpatientsinturkey
AT abbasogluosman theinvestigationofstrongyloidesstercoralisseroprevalenceinimmunosupressedpatientsinturkey
AT aksoysercan theinvestigationofstrongyloidesstercoralisseroprevalenceinimmunosupressedpatientsinturkey
AT akyonyilmazyakut theinvestigationofstrongyloidesstercoralisseroprevalenceinimmunosupressedpatientsinturkey
AT erguvensibel theinvestigationofstrongyloidesstercoralisseroprevalenceinimmunosupressedpatientsinturkey
AT kayafiliz investigationofstrongyloidesstercoralisseroprevalenceinimmunosupressedpatientsinturkey
AT inkayaahmetcagkan investigationofstrongyloidesstercoralisseroprevalenceinimmunosupressedpatientsinturkey
AT ertenlialiihsan investigationofstrongyloidesstercoralisseroprevalenceinimmunosupressedpatientsinturkey
AT abbasogluosman investigationofstrongyloidesstercoralisseroprevalenceinimmunosupressedpatientsinturkey
AT aksoysercan investigationofstrongyloidesstercoralisseroprevalenceinimmunosupressedpatientsinturkey
AT akyonyilmazyakut investigationofstrongyloidesstercoralisseroprevalenceinimmunosupressedpatientsinturkey
AT erguvensibel investigationofstrongyloidesstercoralisseroprevalenceinimmunosupressedpatientsinturkey